Pages that link to "Q36625238"

The following pages link to Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer (Q36625238):

Displaying 35 items.

• Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (Q26780387) (← links)
• Individualized medicine enabled by genomics in Saudi Arabia (Q26861059) (← links)
• Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation (Q27322795) (← links)
• Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? (Q33751398) (← links)
• The Fibroblast Growth Factor signaling pathway (Q34467171) (← links)
• Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors (Q34525925) (← links)
• Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models. (Q35026818) (← links)
• Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer (Q35069479) (← links)
• WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. (Q35133487) (← links)
• Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome (Q35623040) (← links)
• Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis (Q36122605) (← links)
• High Expression of FGFR4 Enhances Tumor Growth and Metastasis in Nasopharyngeal Carcinoma (Q36214131) (← links)
• Electrochemical sensor for rapid determination of fibroblast growth factor receptor 4 in raw cancer cell lysates (Q36334104) (← links)
• Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. (Q36689039) (← links)
• FGF18 as a prognostic and therapeutic biomarker in ovarian cancer (Q37200903) (← links)
• Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer (Q37688471) (← links)
• Prognostic biomarkers in endometrial and ovarian carcinoma (Q38185940) (← links)
• Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. (Q38205584) (← links)
• Ovarian cancer: diagnostic, biological and prognostic aspects (Q38261795) (← links)
• The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer (Q38812018) (← links)
• Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer (Q38830668) (← links)
• Photoactivation approaches reveal a role for Rab11 in FGFR4 recycling and signalling (Q39019114) (← links)
• Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity (Q39382063) (← links)
• Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma (Q41166121) (← links)
• Fibroblast growth factor signaling is required for early somatic gonad development in zebrafish. (Q41702266) (← links)
• MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload (Q49379816) (← links)
• How can molecular abnormalities influence our clinical approach. (Q49896005) (← links)
• Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma. (Q55195623) (← links)
• Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors. (Q55669491) (← links)
• ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression (Q60949960) (← links)
• Helicobacter pylori-Induced DNA Damage Is a Potential Driver for Human Gastric Cancer AGS Cells (Q64087003) (← links)
• Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study (Q89603454) (← links)
• Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression (Q90181992) (← links)
• Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma (Q91865165) (← links)
• FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis (Q92564992) (← links)